Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Four Oxford clinical medical students placed in top 10% in prestigious national Ophthalmology Duke Elder Prize Examination.

The Royal College of Ophthalmology's annual Prize Examination is open to medical undergraduates and this year, 458 students from 38 medical schools across the UK and Ireland took part.  

  • John Logan (6th year Clinical Medical student, St Edmund Hall) gained an impressive 7th place
  • Benjamin Ng (6th year, Christ Church College) placed 8th
  • Veronika Lipkova (3rd year Graduate Entry, St Hugh’s College) placed 14th
  • Keiko Miyazaki (3rd year Graduate Entry, Green Templeton College) was placed in the top 10%

The Royal College of Ophthalmology advise that the standard of the exam is deliberately high and those students taking the top places are to be congratulated. The names of students gaining a top 20 place are published and the candidate gaining the highest mark is offered the chance to visit St John’s Eye Hospital in Jerusalem or a monetary prize of £400. 

Questions are mostly based on clinical ophthalmology but other areas covered include ocular physiology, anatomy and pathology as well as genetics of eye conditions and socio-economic medicine relevant to ophthalmology  (for example, blind registration or world blindness).  In the clinical questions all the sub-speciality areas within ophthalmology are covered.

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.